Patents by Inventor Devin Koestler

Devin Koestler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD TO MEASURE MYELOID SUPPRESSOR CELLS FOR DIAGNOSIS AND PROGNOSIS OF CANCER
    Publication number: 20230193400
    Abstract: Ratio of neutrophils to lymphocytes (NLR) is here associated with immune suppression and decreased survival times in multiple solid tumors. Based on immune cell-specific DMRs and validated cell deconvolution algorithms, the NLR in blood from glioma patients was estimated and glioma patients had elevated mdNLR scores compared to controls. The patient mdNLR scores were increased in patients with grade IV tumors compared to grade II/III. High mdNLR scores were associated with shorter survival. Candidate single (myeloid-associated) gene loci that were highly correlated with the mdNLR were identified. Single myeloid differentiation loci provide a simpler and cheaper alternative to the mdNLR, which requires complex array data. Immunomethylomics are useful and more convenient than conventional cell analysis in profiling glioma risk and survival.
    Type: Application
    Filed: September 30, 2022
    Publication date: June 22, 2023
    Inventors: Karl Kelsey, John Wiencke, Devin Koestler, Brock Christensen
  • A METHOD TO MEASURE MYELOID SUPPRESSOR CELLS FOR DIAGNOSIS AND PROGNOSIS OF CANCER
    Publication number: 20190284636
    Abstract: Ratio of neutrophils to lymphocytes (NLR) is here associated with immune suppression and decreased survival times in multiple solid tumors. Based on immune cell-specific DMRs and validated cell deconvolution algorithms, the NLR in blood from glioma patients was estimated and glioma patients had elevated mdNLR scores compared to controls. The patient mdNLR scores were increased in patients with grade IV tumors compared to grade II/III. High mdNLR scores were associated with shorter survival. Candidate single (myeloid-associated) gene loci that were highly correlated with the mdNLR were identified. Single myeloid differentiation loci provide a simpler and cheaper alternative to the mdNLR, which requires complex array data. Immunomethylomics are useful and more convenient than conventional cell analysis in profiling glioma risk and survival.
    Type: Application
    Filed: October 26, 2017
    Publication date: September 19, 2019
    Applicants: BROWN UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, UNIVERSITY OF KANSAS, THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Karl Kelsey, John Wiencke, Devin Koestler, Brock Christensen